SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?


To: xcr600 who wrote (11793)4/26/2003 6:01:17 PM
From: Bucky Katt  Read Replies (3) | Respond to of 48461
 
Abbott, Fisher to sell West Nile test--SARS test coming>




April 26, 2003

Abbott Laboratories has entered into a marketing agreement with another company to sell a medical test to detect the West Nile virus in infected mosquitoes, the company told shareholders Friday at their annual meeting.

Chief Executive Miles White said the diagnostic will be a "rapid test" for use by public health agencies "to detect West Nile virus in mosquitoes and birds, the reservoirs for the virus."

The North Chicago-based medical product firm will co-market the test with Fisher Scientific International Inc.'s Medical Analysis Systems unit, the product's developer, as part of a deal to sell Fisher's VecTest family of diagnostics, including products used to detect malaria and a form of encephalitis.

White also told shareholders that Abbott is developing its own test to detect human antibodies to the virus in recently infected people. The company plans to submit the test early this summer to the Food and Drug Administration for possible approval.

In rare instances, a West Nile virus infection can result in severe illness or be fatal, according to public health experts. The disease typically spreads by the bite of an infected mosquito.

On Thursday, Abbott said it was close to agreement with an undisclosed firm to distribute a test to detect the deadly SARS virus, but didn't release any more details Friday.
((Ugh, poor old XTRN should have had this test))

chicagotribune.com